| Identification | Back Directory | [Name]
GYY 4137 Morpholine salt | [CAS]
106740-09-4 | [Synonyms]
GYY 4137
GYY 4137 MORPHOLINE SALT
GYY4137;GYY-4137;GYY 4137
morpholin-4-ium (4-methoxyphenyl)(morpholino)phosphinodithioate
4-Methoxyphenyl(morpholino)phosphinodithioate morpholinium salt
P-(4-Methoxyphenyl)-P-4-morpholinylphosphinodithioic acid morpholine salt
(4-Methoxyphenyl)morpholino-phosphinodithioic acid compound with morpholine
(4-methoxyphenyl)-morpholin-4-yl-sulfanylidene-sulfido-λ5-phosphane,morpholin-4-ium | [Molecular Formula]
C15H25N2O3PS2 | [MDL Number]
MFCD18428020 | [MOL File]
106740-09-4.mol | [Molecular Weight]
376.474 |
| Chemical Properties | Back Directory | [Melting point ]
164-166℃ | [storage temp. ]
2-8°C | [solubility ]
DMF: 20 mg/ml; DMSO: 15 mg/ml; PBS (pH 7.2): 3 mg/ml | [form ]
White solid. | [color ]
White |
| Hazard Information | Back Directory | [Description]
Hydrogen sulfide (H2S) is a gaseous mediator which, like nitric oxide (NO), has numerous profound actions in mammalian physiology. GYY 4137 is a water-soluble, slow-releasing hydrogen sulfide (H2S) donor. When given intravenously, it demonstrates vasodilator and anti-hypertensive activity in rats, in either the acute (L-NAME-induced) or chronic (spontaneously hypertensive) hypertension models. Intravenous GYY 4137 also protects against endotoxic shock in rats, inhibiting tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 production and reducing NF-κB activation, iNOS and cyclooxygenase-2 expression, and NO and prostaglandin E2 generation. | [Uses]
Hydrogen sulfide (H2S) is a gaseous mediator which, like nitric oxide (NO), has numerous profound actions in mammalian physiology. GYY 4137 is a water-soluble, slow-releasing hydrogen sulfide (H2S) donor. When given intravenously, it demonstrates vasodilator and anti-hypertensive activity in rats, in either the acute (L-NAME-induced) or chronic (spontaneously hypertensive) hypertension models. Intravenous GYY 4137 also protects against endotoxic shock in rats, inhibiting tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 production and reducing NF-κB activation, iNOS and cyclooxygenase-2 expression, and NO and prostaglandin E2 generation.[Cayman Chemical] | [in vivo]
GYY4137 (100-300 mg/kg; i.p.; daily for 14 days) significantly reduces the tumor volume in both animal models, in a dose-dependent manner[2].
In the complete Freund's adjuvant (CFA)-treated mouse, GYY4137 (50 mg/kg, i.p.) injected 1 hr prior to CFA increased knee joint swelling while an anti-inflammatory effect, as demonstrated by reduced synovial fluid myeloperoxidase (MPO) and N-acetyl-β-D-glucosaminidase (NAG) activity and decreased TNF-α, IL-1β, IL-6 and IL-8 concentration, was apparent when GYY4137 was injected 6 hrs after CFA[3].
GYY4137 significantly inhibited tumor growth in the subcutaneous HepG2 xenograft model by inhibiting STAT3 activation and its target gene expression[4].
GYY4137 prevents nitrative stress and α-synuclein nitration in an MPTP mouse model of parkinson’s disease[5]. | Animal Model: | Female, severe combined immunodeficiency (SCID) mice (bearing HL-60 or MV4-11 cells)[2] | | Dosage: | 100, 200 and 300 mg/kg | | Administration: | I.p.; daily for 14 days | | Result: | Reduced tumor volume by 52.5% and 55.3% in HL-60 and MV4–11 injected animals.
|
| [IC 50]
Stat-3 | [storage]
+4°C |
|
|